Just four months after its lead therapy lirilumab flunked a mid-stage test fighting acute myeloid leukemia, France’s Innate Pharma has exchanged a chunk of equity for a new immuno-oncology drug candidate from Novo Nordisk.
The drug — which Novo has tested in a pair of Phase I rheumatoid arthritis studies — is an anti-C5aR antibody aimed at the “accumulation and activation of myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment.”
Innate is giving Novo Nordisk an upfront payment of €40 million, of which €37.2 million is coming in new Innate Pharma shares, with only €2.8 million in cash. Novo Nordisk will be eligible for €370 million in development, regulatory and sales milestone payments as well as double-digit royalties on net sales.
Innate CEO Mondher Mahjoubi commented:
With the acquisition of the first-in-class anti-C5aR antibody, we are broadening our proprietary clinical pipeline. We believe anti-C5aR has a high potential for cancer patients in multiple indications and look forward to beginning clinical development of this promising asset in 2018. Innate Pharma has a strong track record of value creation from in-licensed assets with lirilumab and monalizumab. This acquisition strengthens our asset base further and supports Innate Pharma’s transition towards becoming a fully-integrated biopharmaceutical company.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription